Sebastiaan Heidt1, Manon Vergunst, Jacqueline D H Anholts, Marlies E J Reinders, Johan W de Fijter, Michael Eikmans, Frans H J Claas. 1. 1 Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands. 2 Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands. 3 Address correspondence to: Sebastiaan Heidt, M.D., Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2-2333 ZA Leiden, the Netherlands.
Abstract
BACKGROUND: Recently, several B cell-related markers have been described to be upregulated during operational tolerance in kidney allograft recipients. Little data exist on these markers during allograft rejection. METHODS: In this study, we investigated regulation-associated B-cell phenotypes in peripheral blood mononuclear cells (PBMCs) of kidney transplant recipients with (n=21) and without (n=22) acute rejection (AR). We also determined expression levels of the B cell-related genes, MS4A1, TCL1A, and CD79B, in PBMCs and isolated B cells. Patient samples were analyzed before transplantation at discharge and at time of AR before initiation of antirejection therapy or at matching timepoints in patients with stable graft function. RESULTS: On transplantation, the peripheral CD19CD24CD38 transitional B cell subset strongly declined, regardless of the subsequent occurrence of AR. In contrast, the CD19CD27CD24 subset remained stable after transplantation in both patients groups. MS4A1 gene expression levels in PBMC were comparable between patient groups at all timepoints. In contrast, TCL1A expression levels increased in stable patients, but decreased in patients at the time of AR in both PBMC and isolated B cells. CD79B expression levels in stable patients were unaltered after transplantation in PBMC but showed an increase in the B cell fraction at discharge. At the time of AR, CD79B gene expression was significantly lower compared to stable patients, being most apparent in the B-cell fraction. CONCLUSION: These results suggest that, in addition to being markers for immunologic unresponsiveness, gene expression levels of TCL1A and CD79B may also identify immune activation in the setting of kidney transplantation.
BACKGROUND: Recently, several B cell-related markers have been described to be upregulated during operational tolerance in kidney allograft recipients. Little data exist on these markers during allograft rejection. METHODS: In this study, we investigated regulation-associated B-cell phenotypes in peripheral blood mononuclear cells (PBMCs) of kidney transplant recipients with (n=21) and without (n=22) acute rejection (AR). We also determined expression levels of the B cell-related genes, MS4A1, TCL1A, and CD79B, in PBMCs and isolated B cells. Patient samples were analyzed before transplantation at discharge and at time of AR before initiation of antirejection therapy or at matching timepoints in patients with stable graft function. RESULTS: On transplantation, the peripheral CD19CD24CD38 transitional B cell subset strongly declined, regardless of the subsequent occurrence of AR. In contrast, the CD19CD27CD24 subset remained stable after transplantation in both patients groups. MS4A1 gene expression levels in PBMC were comparable between patient groups at all timepoints. In contrast, TCL1A expression levels increased in stable patients, but decreased in patients at the time of AR in both PBMC and isolated B cells. CD79B expression levels in stable patients were unaltered after transplantation in PBMC but showed an increase in the B cell fraction at discharge. At the time of AR, CD79B gene expression was significantly lower compared to stable patients, being most apparent in the B-cell fraction. CONCLUSION: These results suggest that, in addition to being markers for immunologic unresponsiveness, gene expression levels of TCL1A and CD79B may also identify immune activation in the setting of kidney transplantation.
Authors: K de Leur; M C Clahsen-van Groningen; T P P van den Bosch; G N de Graav; D A Hesselink; J N Samsom; C C Baan; K Boer Journal: Clin Exp Immunol Date: 2018-02-02 Impact factor: 4.330
Authors: Ondrej Viklicky; Petra Hruba; Stefan Tomiuk; Sabrina Schmitz; Bernhard Gerstmayer; Birgit Sawitzki; Patrick Miqueu; Petra Mrazova; Irena Tycova; Eva Svobodova; Eva Honsova; Uwe Janssen; Hans-Dieter Volk; Petra Reinke Journal: PLoS One Date: 2017-01-13 Impact factor: 3.240
Authors: Juan Irure-Ventura; David San Segundo; Emilio Rodrigo; David Merino; Lara Belmar-Vega; Juan Carlos Ruiz San Millán; Rosalía Valero; Adalberto Benito; Marcos López-Hoyos Journal: Int J Mol Sci Date: 2020-01-25 Impact factor: 5.923
Authors: Eman H Ibrahim; Mostafa Aly; Christian Morath; Douaa M Sayed; Naruemol Ekpoom; Gerhard Opelz; Caner Süsal; Volker Daniel Journal: Immun Inflamm Dis Date: 2021-06-08